BLRD Research Career Scientist Award Application
BLRD 研究职业科学家奖申请
基本信息
- 批准号:10594019
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-04-01 至 2027-03-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAffectApoptosisAreaAwardBiological ModelsCD44 geneCD8B1 geneCancer PatientCause of DeathCell LineageCellsCessation of lifeClinical TrialsClonal ExpansionCollaborationsDNA DamageDNA RepairDNA Repair PathwayDefectDevelopmentDisseminated Malignant NeoplasmDistant MetastasisEpitheliumExposure toFibroblastsFundingGeneral PopulationGenesGenetic EngineeringGenomicsGoalsGrowthHead and Neck Squamous Cell CarcinomaHead and neck structureHealthHealthcareHumanImmuneImmune EvasionImmune systemImmunologic SurveillanceImmunosuppressionImmunosuppressive AgentsImmunotherapyIndolentInterventionInvadedInvestigational TherapiesLaboratoriesLinkLoss of HeterozygosityLungMADH4 geneMalignant Epithelial CellMalignant NeoplasmsMediatingMetastatic Squamous Cell CarcinomaModelingMyeloid CellsNeoplasm MetastasisOral cavityOrganOutcomePIK3CG genePathologicPatientsPlayPopulationPredispositionProductionPrognostic MarkerPropertyProtein SecretionRadiation therapyReportingResearchResearch PersonnelResourcesRoleScientistSiteSkinSquamous cell carcinomaStratified EpitheliumStromal CellsT-Cell ReceptorT-LymphocyteTherapeutic InterventionTimeTobacco-Associated CarcinogenTransforming Growth Factor betaTranslatingTumor ImmunityTumor Suppressor ProteinsTumor-associated macrophagesUp-RegulationVeteransWNT Signaling Pathwayangiogenesisbiomarker identificationcancer cellcancer sitecancer stem cellcancer typecare outcomescareerclinical diagnosisclinical prognosiscytotoxicdesigneffective therapyexperimental studyhigh riskhuman genome sequencingimprovedinnovationliquid biopsymelanomamigrationmilitary veteranmouse modelmultipotent cellmutantneoantigensneoplastic cellpharmacodynamic biomarkerprognosis biomarkerprognostic valueprogrammed cell death ligand 1programspromoterrecruitskin squamous cell carcinomastem cell expansionstem cell nichetargeted cancer therapytherapeutic biomarkertherapeutic evaluationtherapeutic targettherapeutically effectivetumortumor eradicationtumor heterogeneitytumor microenvironmenttumor progressionultraviolet irradiationwhole genome
项目摘要
The overarching objective of my research program is to identify markers for prognosis and therapeutic
interventions for squamous cell carcinomas (SCCs), hence improving health outcomes for veterans. SCCs arise
from stratified epithelia; the most relevant organ sites in veterans are the skin and oral cavity where high
exposure to UV irradiation and tobacco carcinogens make the total and high-risk SCCs significantly higher than
in the civilian population. The worst outcome of SCC is death caused by distant metastasis. Skin SCC deaths
exceed melanoma deaths and SCC deaths in the head and neck are 3-4 times higher than skin SCC deaths.
The long-term goal of my VA research program is to identify markers for prognosis and therapeutic interventions
for SCCs, hence improving health outcomes for veterans. Since being funded in 2016 by a VA Merit Award, my
laboratory has been studying mechanisms related to SCC progression and therapeutic interventions. These
studies continuously translate into clinical diagnosis and therapeutic interventions directly impacting veterans’
healthcare outcomes. My laboratory pioneered inducible and epithelial-specific genetic engineered mouse
models (GEMMs) that develop SCCs and metastasis in the natural microenvironment and immune system.
These models provide unique resources for cross-species comparisons with human SCCs and performing
experimental therapeutics, including immunotherapy, in my past and ongoing Merit Award research. SCCs are
often indolent for decades. In the previous funding period, we focused on studying how SCCs break indolence
to become aggressive and metastatic cancers. We found that the properties of a subset of cancer stem cells
(CSCs) are responsible for breaking indolence through both clonogenicity and invasion. We found that
“heterozygous loss” of SMAD4, a tumor suppressor, in 30-50% of head and neck SCCs in humans, is a result of
significant inter- and intra-tumor heterogeneity at the single cell level, and that SMAD4 mutant cells have a
growth/survival advantage allowing them to take over the entire population of tumor cells. These findings
provide critical prognostic value for examining SMAD4 genomic status at the single cell level. Further, SMAD4-
deficient SCC cells have “Brca-like” defects in DNA damage repair that are susceptible to cancer
therapies that target DNA repair pathways. This finding provides an important link for a therapeutic marker
and strategy, and instigated an investigator-initiated clinical trial to treat locally advanced head and neck SCC
with radiotherapy (RT) in combination with Olaparib, which included recruiting VA patients. In tumor stroma, we
found that SMAD4 genomic loss triggers overproduction of TGFβ1, an immune suppressor and promoter for
cancer progression. In addition, cancer associated fibroblasts (CAFs) secret more TGFβ than cancer cells
and provide a CSC niche at the distant metastasis site for CSC clonal expansion. We also found that
tumor-associated macrophages (TAMs) contribute to breaking indolence by CSC expansion through anti-
apoptosis and angiogenesis. Further, SMAD4 mutant SCC cells have advantages in clonogenicity and
immune evasion but paradoxically produce more DNA damage-associated neoantigens susceptible to
anti-tumor immunity, pointing to therapeutic intervention strategies. We identified that SCCs with Smad4 loss
changed the TME to be TGFβ and PD-L1-rich in myeloid cells, which are highly susceptible to immune
eradication by dual TGFβ/PD-L1 targeting. These findings are ready to be translated to a clinical trial of
radiotherapy in combination with dual TGFβ/PD-L1 targeting in advanced head and neck SCC patients including
VA patient accrual, thus bringing therapeutic intervention in real time to our veterans. Ongoing research areas
include: 1) Assess intrinsic properties of SCC cells that contribute to self-autonomous expansion and metastasis.
2) Identify SCC metastatic niche established by stromal cells. 3) Identify mechanisms of SCC immune evasion
and immunotherapy interventions for SCCs.
我的研究计划的首要目标是确定预后和治疗的标志物
对鳞状细胞癌(SCCs)的干预,从而改善退伍军人的健康结果。SCCS产生
来自复层上皮;退伍军人最相关的器官部位是皮肤和口腔,在那里
暴露于紫外线照射和烟草致癌物使总的和高危的体细胞显著高于
在平民人口中。鳞状细胞癌最糟糕的结局是远处转移导致的死亡。皮肤鳞状细胞癌死亡
超过黑色素瘤死亡和头颈部鳞状细胞癌死亡人数是皮肤鳞状细胞癌死亡人数的3-4倍。
我的退伍军人事务部研究计划的长期目标是确定预后和治疗干预的标志
对于SCC来说,因此改善了退伍军人的健康结果。自从2016年获得退伍军人事务部荣誉奖以来,我的
实验室一直在研究与鳞癌进展和治疗干预相关的机制。这些
研究不断转化为临床诊断和治疗干预,直接影响退伍军人的
医疗保健结果。我的实验室率先开发了可诱导的上皮特异性基因工程小鼠
在自然微环境和免疫系统中发展SCC和转移的模型(GEMM)。
这些模型为与人类SCC进行跨物种比较和执行
实验疗法,包括免疫疗法,在我过去和正在进行的功勋奖研究。SCC是
往往懒惰了几十年。在之前的资助期间,我们重点研究了SCC如何打破懒惰
变成侵袭性和转移性癌症。我们发现一组癌症干细胞的特性
(CSCs)负责通过克隆形成和入侵来打破惰性。我们发现
在人类30%-50%的头颈部SCC中,肿瘤抑制基因Smad4的“杂合性丢失”是由
在单细胞水平上存在显著的肿瘤内和肿瘤内异质性,并且Smad4突变细胞具有
生长/存活优势使它们能够接管整个肿瘤细胞群。这些发现
为在单细胞水平上检测Smad4基因组状态提供关键的预后价值。此外,Smad4-
有缺陷的SCC细胞在DNA损伤修复中有“BRCA样”缺陷,易患癌症
针对DNA修复途径的疗法。这一发现为治疗标记物提供了一个重要的联系
和策略,并发起了一项由研究人员发起的临床试验,以治疗局部晚期头颈部鳞状细胞癌
放射治疗(RT)联合奥拉帕利,包括招募VA患者。在肿瘤间质中,我们
研究发现,Smad4基因组缺失会触发转化生长因子β1的过度生产,转化生长因子Smad1是一种免疫抑制因子,也是
癌症进展。此外,癌症相关成纤维细胞(CAF)比癌细胞分泌更多的转化生长因子β
为CSC的克隆扩增提供了远处转移部位的CSC生态位。我们还发现,
肿瘤相关巨噬细胞(TAMs)通过抗肿瘤相关巨噬细胞(TAMs)的抗肿瘤效应,促进CSC的扩张,从而打破惰性
细胞凋亡和血管生成。此外,Smad4突变的SCC细胞在克隆形成和
免疫逃避,但矛盾的是,产生更多与DNA损伤相关的新抗原,容易感染
抗肿瘤免疫,指向治疗干预策略。我们发现Smad4缺失的鳞状细胞
将TME改为富含转化生长因子β和PD-L1的髓系细胞,这两种细胞对免疫易感
转化生长因子β/PD-L1双靶向治疗。这些发现已经准备好转化为临床试验。
放疗联合双重转化生长因子β/PD-L1靶向治疗晚期头颈部鳞癌
为退伍军人带来实时的治疗干预。正在进行的研究领域
包括:1)评估有助于自我扩张和转移的SCC细胞的固有特性。
2)确定由基质细胞建立的鳞癌转移生态位。3)确定鳞状细胞癌免疫逃避机制
以及对干细胞的免疫治疗干预。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Xiao-Jing Wang其他文献
Xiao-Jing Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Xiao-Jing Wang', 18)}}的其他基金
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10477461 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10704598 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Treating recurrent HNSCC with radiation and dual TGF-Beta/PD-L1.
使用放射和双重 TGF-Beta/PD-L1 治疗复发性 HNSCC。
- 批准号:
10268846 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Mechanisms of Breaking Indolence in Squamous Cell Carcinoma
打破鳞状细胞癌惰性的机制
- 批准号:
9137250 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
- 批准号:
10731726 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Mechanisms and Therapeutic Targets of SCC Metastasis
SCC转移的机制和治疗靶点
- 批准号:
10356069 - 财政年份:2016
- 资助金额:
-- - 项目类别:
Testing Smad7-based biologics for treating chronic wounds
测试基于 Smad7 的生物制剂治疗慢性伤口
- 批准号:
8779367 - 财政年份:2014
- 资助金额:
-- - 项目类别:
相似海外基金
How Does Particle Material Properties Insoluble and Partially Soluble Affect Sensory Perception Of Fat based Products
不溶性和部分可溶的颗粒材料特性如何影响脂肪基产品的感官知觉
- 批准号:
BB/Z514391/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Training Grant
BRC-BIO: Establishing Astrangia poculata as a study system to understand how multi-partner symbiotic interactions affect pathogen response in cnidarians
BRC-BIO:建立 Astrangia poculata 作为研究系统,以了解多伙伴共生相互作用如何影响刺胞动物的病原体反应
- 批准号:
2312555 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
RII Track-4:NSF: From the Ground Up to the Air Above Coastal Dunes: How Groundwater and Evaporation Affect the Mechanism of Wind Erosion
RII Track-4:NSF:从地面到沿海沙丘上方的空气:地下水和蒸发如何影响风蚀机制
- 批准号:
2327346 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Standard Grant
Graduating in Austerity: Do Welfare Cuts Affect the Career Path of University Students?
紧缩毕业:福利削减会影响大学生的职业道路吗?
- 批准号:
ES/Z502595/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Fellowship
感性個人差指標 Affect-X の構築とビスポークAIサービスの基盤確立
建立个人敏感度指数 Affect-X 并为定制人工智能服务奠定基础
- 批准号:
23K24936 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (B)
Insecure lives and the policy disconnect: How multiple insecurities affect Levelling Up and what joined-up policy can do to help
不安全的生活和政策脱节:多种不安全因素如何影响升级以及联合政策可以提供哪些帮助
- 批准号:
ES/Z000149/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
How does metal binding affect the function of proteins targeted by a devastating pathogen of cereal crops?
金属结合如何影响谷类作物毁灭性病原体靶向的蛋白质的功能?
- 批准号:
2901648 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Studentship
Investigating how double-negative T cells affect anti-leukemic and GvHD-inducing activities of conventional T cells
研究双阴性 T 细胞如何影响传统 T 细胞的抗白血病和 GvHD 诱导活性
- 批准号:
488039 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
New Tendencies of French Film Theory: Representation, Body, Affect
法国电影理论新动向:再现、身体、情感
- 批准号:
23K00129 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
The Protruding Void: Mystical Affect in Samuel Beckett's Prose
突出的虚空:塞缪尔·贝克特散文中的神秘影响
- 批准号:
2883985 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Studentship